Quick Answer
Tvardi Therapeutics, Inc. reported Research And Development Expense of $18.01 million for the year ending 2025.
- Tvardi Therapeutics, Inc. showed a decrease of -23.8% in Research And Development Expense from 2024 to 2025.
- This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Tvardi Therapeutics, Inc.'s Research And Development Expense has grown by 291.8%.
- Historical annual values: Fiscal year 2025: $18.01 million | Fiscal year 2024: $23.65 million | Fiscal year 2023: $108.51 million | Fiscal year 2022: $91.88 million | Fiscal year 2021: $82.70 million | Fiscal year 2020: $107.85 million | Fiscal year 2019: $113.82 million | Fiscal year 2018: $75.53 million | Fiscal year 2017: $48.52 million | Fiscal year 2016: $49.25 million | Fiscal year 2015: $21.22 million | Fiscal year 2014: $15.07 million | Fiscal year 2013: $8.69 million | Fiscal year 2012: $4.60 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: